Company announcements

2022

2021

2020

2019

2022

27 September

Result of AGM

20 September

Interim results for the six-months ended 30 June 2022

12 September

Change of Interim Results Date

05 September

Notice of results

01 September

Notice of AGM & Proposed new 2022 Long Term Incentive Plan

30 August

Spectral MD Awarded an Additional $8.2M of Funding from BARDA

19 August

Grant of Options

07 July

Stockholder waiver granted

23 June

Removal of Regulation S restrictions from shares of common stock

17 June

Mediscience Award Win

13 June

Diabetic Foot Ulcer Clinical Validation Study Initiated

10 May

Publication of Annual Financial Report

13 April

Appointment of Christine Marks as Vice President of Marketing and Commercialisation

21 March

Final results

09 March

Notice of Full Year Results

04 February

Grant of share options and cash bonus

01 February

Full Year Trading update and Notice of Results

11 January

Director/PDMR Shareholding

2021

23 December

Share Dealing and Exercise of Options

21 December

Grant of share options and Management update

01 December

Appointment of Chief Financial Officer

18 November

Enrolment completed for multi-center study for Diabetic Foot Ulcers ("DFU")

16 November

Early results from clinical study presented at major U.S. burn conference

20 October

Appointment of Joint Broker

11 October

Grant of share options

13 September

Half-Year Report

07 September

Notice of Interim Results

06 September

BARDA approval of additional $18.8m funding

09 August

Spectral MD hosts event to launch a multi-center clinical study for burn wounds

15 July

Holding(s) in Company

24 June

Contract Award from US Department of Defense

22 June

Admission to trading on AIM & First Day of Dealings

16 June

Conditional Placing to raise approximately £11.3 million (US$16.0 million)

07 June

Intention to Float on AIM

20 April

Dallas health-tech company gets over $20M more in funding

07 April

BARDA Approval of Additional Funding of $20.6 Million to Execute DeepView Training Clinical Study for Burn Wounds

02 February

Spectral MD Completes Expanded Proof-of-Concept (ePOC) Multi-Center Clinical Study for Burn Wounds

2020

17 December

Spectral MD Initiates Multi-Center Clinical Study for Diabetic Foot Ulcer

17 December

Spectral MD and RCSI to Advance Care for Chronic Wounds

01 December

Spectral MD Appoints Dr. Jeffrey Carter as Chief Medical Consultant and Wan Lung Eng as Chief Financial Officer

21 July

Spectral MD and the American College of Cardiology to Advance Care for Critical Limb Ischemia

29 June

Spectral MD Names New CEO

03 June

Spectral MD and BARDA Agree to Start Enrollment in Clinics for Expanded Proof Of Concept Study (ePOC) Stage II Using the Company’s Improved DeepView SnapShot® Device

19 May

Spectral MD Welcomes Former Cleveland Clinic CEO Toby Cosgrove to the Spectral MD Board of Advisors

07 January

New technology at UMC Burn Center

2019

15 August

Modernizing wound care with Spectral MD, powered by Amazon SageMaker

23 July

Spectral MD Receives Substantial Funding from BARDA for Continued Development of Spectral MD’s DeepView® Biomedical Imaging Device

19 July

U.S. Invests In Burn Imaging Device For Mass Casualty Preparedness

18 July

U.S. Department of Health and Human Services (HHS) sponsors development of portable, user-friendly burn imaging device

Company Announcements

2022

2021

2020

2019